West Pharmaceutical Services (WST)
(Real Time Quote from BATS)
$315.04 USD
-1.46 (-0.46%)
Updated Nov 4, 2024 03:55 PM ET
After-Market: $316.20 +1.16 (0.37%) 4:18 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$315.04 USD
-1.46 (-0.46%)
Updated Nov 4, 2024 03:55 PM ET
After-Market: $316.20 +1.16 (0.37%) 4:18 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Zacks News
What's in Store for Henry Schein (HSIC) in Q3 Earnings?
by Zacks Equity Research
Strengthening demand in the global dental and medical markets along with the recent investments are likely to have contributed to Henry Schein's (HSIC) Q3 performance.
SmileDirectClub (SDC) Introduces Two New Water Flossers
by Zacks Equity Research
SmileDirectClub (SDC) launched the new Large Tank and Compact Water Flossers, currently available at Shop.SmileDirectClub.com, Amazon, Walmart and Walmart.com.
Breast Health Sales to Drive Hologic's (HOLX) Q4 Earnings
by Zacks Equity Research
The acquisition of Biotheranostics and the launch of new software are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the fourth quarter.
Catalent (CTLT) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q1 results.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its fourth-quarter performance.
QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold
by Zacks Equity Research
QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.
PDCO vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. WST: Which Stock Is the Better Value Option?
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Recovery in Clinical Diagnostics arm and strong growth in Droplet Digital PCR platform are expected to have contributed to Bio-Rad's (BIO) Q3 results.
West Pharmaceutical Services (WST) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Q3 Earnings Top Estimates, View Up
by Zacks Equity Research
Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.
What's in Store for West Pharmaceutical's (WST) Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Continued strong adoption of Invisalign Clear Aligners and iTero scanners is expected to contribute to Align Technology's (ALGN) third-quarter 2021 results.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Abbott's (ABT) Q3 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Abbott's (ABT) COVID-19 testing-related sales in Q3 increase on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.
QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.
Intuitive Surgical's (ISRG) Ion System Backed by Clinical Study
by Zacks Equity Research
Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.
Abbott's (ABT) Nutrition Arm in Focus on Real Madrid Alliance
by Zacks Equity Research
According to Abbott (ABT), the partnership is set to support education, sports and social welfare activities of at-risk children in 80 countries.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.
LHC Group (LHCG) Reports Impressive Preliminary Q3 Revenues
by Zacks Equity Research
Growth in LHC Group's (LHCG) revenues in the third quarter is likely to have been boosted by continued strength in its home health and hospice services.
PerkinElmer's (PKI) New Deal to Improve Single-Cell Profiling
by Zacks Equity Research
PerkinElmer (PKI) partners with Honeycomb Biotechnologies to launch HIVE scRNAseq Solution, which can advance single-cell profiling.
Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and raised 2021 earnings guidance.
NuVasive (NUVA) Announces Two Developments in Cohere TLIF Line
by Zacks Equity Research
According to NuVasive (NUVA), Porous PEEK is a clear differentiator for the company in the market.